Efficacy of ferric carboxymaltose on haemoglobin response among older patients with gastrointestinal bleeding: a randomised clinical trial.

Background: Acute gastrointestinal bleeding (AGIB) is common in older patients but the use of iron in this context remains understudied.

Aims: This study aimed to evaluate prospectively the efficacy of ferric carboxymaltose to treat anaemia in older patients after AGIB.

Methods: This randomised double-blinded placebo-controlled clinical trial was conducted in 10 French centres.

Prognostic factors associated with upper gastrointestinal bleeding based on the French multicenter SANGHRIA trial.

 Prognostic and risk factors for upper gastrointestinal bleeding (UGIB) might have changed overtime because of the increased use of direct oral anticoagulants and improved gastroenterological care. This study was undertaken to assess the outcomes of UGIB in light of these new determinants by establishing a new national, multicenter cohort 10 years after the first.  Consecutive outpatients and inpatients with UGIB symptoms consulting at 46 French general hospitals were prospectively included between November 2017 and October 2018.